Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod

Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

(2015) John G. Hanly et al.   Arthritis & Rheumatology

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

(2014) R A Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

(2013) Vibeke Strand et al.   ANNALS OF THE RHEUMATIC DISEASES

Biosimilars in rheumatology: perspective and concerns

(2013) M. A. Scheinberg et al.   RHEUMATOLOGY

Disease-Specific Patient Reported Outcome Tools for Systemic Lupus Erythematosus

(2012) Meenakshi Jolly et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Numerical scoring for the BILAG-2004 index

(2010) Chee-Seng Yee et al.   RHEUMATOLOGY